Talk:Dabigatran
From Wikipedia, the free encyclopedia
 |
Dabigatran is part of WikiProject Pharmacology, a project to improve all Pharmacology-related articles. If you would like to help improve this and other pharmacology articles, please join the project. All interested editors are welcome. |
| Start | This article has been rated as start-Class on the quality scale. |
| Mid | This article has been rated as mid-importance for this Project's importance scale. |
|
|
|
150 mg bd for stroke - publication awaited. JFW | T@lk 07:56, 1 August 2006 (UTC)
- More on the PETRO and PETRO-Ex trials. JFW | T@lk 07:59, 1 August 2006 (UTC)
Animal model: doi:10.1111/j.1538-7836.2007.02526.x JFW | T@lk 20:12, 27 March 2007 (UTC)
[edit] VTE post knee replacement
doi:10.1111/j.1538-7836.2007.02748.x - RE-MODEL trial showed non-inferiority to enoxaparin and no difference in liver enzymes. JFW | T@lk 21:32, 2 September 2007 (UTC)
- doi:10.1016/S0140-6736(07)61445-7 Lancet study (RE-NOVATE) shows comparable efficacy to enoxaparin. JFW | T@lk 00:25, 16 September 2007 (UTC)
I edited the IUPAC Name to simplify it...--ChemSpiderMan (talk) 19:21, 16 December 2007 (UTC)
When you edited the IUPAC Name, did you notice, that it contaíns a (2-pyridinyl)-group and in the picture above it´s a 3-pyridinyl? I suppose the picture is wrong. Besides, it shows the pro-drug Dabigatran-etexilat and not Dabigatran itself. —Preceding unsigned comment added by 88.116.119.194 (talk) 14:40, 16 May 2008 (UTC)
[edit] Bags of trials
http://www.pradaxa.com/HCP/Home/clinical_trials/index.htm (for non-US based healthcare professionals only, apparently). JFW | T@lk 20:31, 12 May 2008 (UTC)
